4//SEC Filing
WACHTER ERIC PHD 4
Accession 0001493152-21-015020
CIK 0000315545other
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 5:23 PM ET
Size
11.4 KB
Accession
0001493152-21-015020
Insider Transaction Report
Form 4
WACHTER ERIC PHD
DirectorVice President Pharmaceuticals
Transactions
- Award
8% Secured Convertible Promissory Notes due 2021
2021-06-17Exercise: $2.86From: 2021-06-17Exp: 2021-06-20→ Series D-1 Convertible Preferred Stok (1,393,276 underlying) - Exercise/Conversion
Series D-1 Convertible Preferred Stock
2021-06-20+1,393,276→ 1,393,276 totalFrom: 2021-06-20→ Common Stock (13,932,760 underlying) - Exercise/Conversion
8% Secured Convertible Promissory Notes due 2021
2021-06-20→ 0 totalExercise: $2.86From: 2021-06-17Exp: 2021-06-20→ Series D-1 Convertible Preferred Stock (1,393,276 underlying)
Footnotes (4)
- [F1]The Issuer issued the 8% secured convertible promissory notes due 2021 to the Reporting Person on various dates in 2017 and January 26, 2018, which were amended on February 12, 2019 (the "Notes"). At the time of issuance, the Issuer had not filed a Certificate of Designation for the Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock") and, therefore, there was no security underlying the Notes into which the Notes could convert. On June 17, 2021, the Issuer filed a Certificate of Designation with the Delaware Secretary of State to create the Series D-1 Convertible Preferred Stock and, upon the filing of the Certificate of Designation, the Notes became a derivative security.
- [F2]On June 20, 2021, the Notes automatically converted into Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the Notes.
- [F3]Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- [F4]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
Documents
Issuer
PROVECTUS BIOPHARMACEUTICALS, INC.
CIK 0000315545
Entity typeother
Related Parties
1- filerCIK 0001124261
Filing Metadata
- Form type
- 4
- Filed
- Jun 21, 8:00 PM ET
- Accepted
- Jun 22, 5:23 PM ET
- Size
- 11.4 KB